| 研究課題/領域番号 |
23K16036
|
|---|
| 研究種目 |
若手研究
|
| 配分区分 | 基金 |
|---|
| 審査区分 |
小区分57040:口腔再生医学および歯科医用工学関連
|
|---|
| 研究機関 | 東京医科歯科大学 |
|---|
研究代表者 |
周 君 東京医科歯科大学, 生体材料工学研究所, 特任助教 (40846507)
|
|---|
| 研究期間 (年度) |
2023-04-01 – 2026-03-31
|
| 研究課題ステータス |
交付 (2023年度)
|
| 配分額 *注記 |
4,550千円 (直接経費: 3,500千円、間接経費: 1,050千円)
2025年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
2024年度: 1,950千円 (直接経費: 1,500千円、間接経費: 450千円)
2023年度: 1,300千円 (直接経費: 1,000千円、間接経費: 300千円)
|
|---|
| キーワード | Wwp2 / mRNA theraputics / Osteoarthritis / mRNA therapy / osteoarthritis / temporomandibular joint |
|---|
| 研究開始時の研究の概要 |
In this study, we propose a TMJOA therapy by using circular RNA (circRNA)-loaded polyplex nanomicelles. Wwp2 circRNA will be administered by intra-articular injection into the TMJ, and the therapeutic outcome will be evaluated by monitoring the nociceptive behaviors and level of inflammation. The molecular mechanisms of Wwp2 message RNA(mRNA) therapy will also be elucidated here.
|
| 研究実績の概要 |
Wwp2 mRNA was successfully established and treated in an in vitro chondrocyte-based osteoarthritis inflammation model using IL-1β induction. This model serves as a valuable tool for evaluating the therapeutic potential of Wwp2 mRNA in the context of OA-associated inflammation. Furthermore, we demonstrated that in vivo delivery of Wwp2 mRNA attenuates OA progression in an animal model, as evidenced by reduced cartilage damage.
|
| 現在までの達成度 (区分) |
現在までの達成度 (区分)
2: おおむね順調に進展している
理由
We totally have 4 aims in this project during the grant applicaiton. In the first year, we completed all tasks related to Aim 1, evaluating the biological function of Wwp2 mRNA therapy in vitro, including the construction of Wwp2 mRNA and the establishment of an in vitro chondrocyte-based OA inflammation model. We also partially fulfilled Aim 2 by developing linear Wwp2 mRNA.
|
| 今後の研究の推進方策 |
In the next stages, we will focus on the remaining objectives: completing Aim 2 (Wwp2 circRNA development), Aim 3 (delivery of Wwp2 circRNA using polyplex nanomicelles), and Aim 4 (investigating TMJOA treatment outcomes and mechanisms using Wwp2 circRNA delivery in vivo).
|
